{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:36:34Z","timestamp":1794893794606,"version":"4.9.1"},"reference-count":20,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2019,7,31]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Psoriasis is a chronic immune-medicated inflammatory condition that affects\n2-3% of the population, which can lead to psoriatic arthritis. There are multiple regimens for\nthe treatment of psoriasis including disease- modifying anti rheumatic drugs (DMARDS) and biologic\nagent, phototherapy and apremilast. While monotherapy with biologic agents is effective for\nmany patients with psoriasis some patients are not satisfied by the outcome and require combination\ntherapy. No data exist on the safety of apremilast as a component of combination therapy with\nbiological therapies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The aim of the study was to determine the safety of apremilast in combination of biologic\ntherapies in the treatment of plaque psoriasis and psoriatic arthritis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This was retrospective study, open label study carried out at a single community Rheumatology\ncenter. Twenty-two patients diagnosed with plaque psoriasis and psoriatic arthritis according\nto American college of Rheumatology criteria-participated. Apremilast was added to their\ncurrent biologic agent. Patients were permitted to their current biologic treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Out of 22 patients, six patients developed side effects, none of which caused discontinuation\nof therapy. Out of the six patients who developed side effects, two patients developed nausea\nand two patients developed diarrhea. One patient developed weight loss and one patient developed\nabdominal pain.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Apremilast can be safely combined with all biologic agents in patients with plaque\npsoriasis or psoriatic arthritis not responding adequately to biologics alone.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573397115666181130094455","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T12:02:02Z","timestamp":1543579322000},"page":"234-237","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis"],"prefix":"10.2174","volume":"15","author":[{"given":"Samy","family":"Metyas","sequence":"first","affiliation":[{"name":"Covina Arthritis Clinic, Covina, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Tomassian","sequence":"additional","affiliation":[{"name":"University of Missouri-Kansas City School of Medicine, Covina, CA 91722, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Messiah","sequence":"additional","affiliation":[{"name":"Covina Arthritis Clinic, Covina, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Gettas","sequence":"additional","affiliation":[{"name":"Covina Arthritis Clinic, Covina, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chen","sequence":"additional","affiliation":[{"name":"Covina Arthritis Clinic, Covina, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Quismorio","sequence":"additional","affiliation":[{"name":"Covina Arthritis Clinic, Covina, CA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","volume":"64","author":"Langley R.G.B.","year":"2005","unstructured":"Langley R.G.B.; Krueger G.G.; Griffiths C.E.M.; Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005,64(Suppl. 2),ii18-ii23","journal-title":"Ann Rheum Dis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"Michalek I.M.","year":"2017","unstructured":"Michalek I.M.; Loring B.; John S.M.; A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017,31(2),205-212","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"Parisi R.","year":"2013","unstructured":"Parisi R.; Symmons D.P.; Griffiths C.E.; Ashcroft D.M.; Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013,133(2),377-385","journal-title":"J Invest Dermatol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"Menter A.","year":"2008","unstructured":"Menter A.; Gottlieb A.; Feldman S.R.; Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008,58(5),826-850","journal-title":"J Am Acad Dermatol"},{"key":"ref=5","volume":"3","author":"Moll JMH","year":"1973","unstructured":"Moll JMH; Wright V;  Psoriatic arthritis Seminars in arthritis and rheumatism WB Saunders1973,3(1)","journal-title":"Psoriatic arthritis Seminars in arthritis and rheumatism"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.5312\/wjo.v5.i4.537","author":"Liu Jung-Tai","year":"2014","unstructured":"Liu Jung-Tai; Psoriatic arthritis: epidemiology, diagnosis, and treatment. World journal of orthopedics 2014,537","journal-title":"World journal of orthopedics"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"Coates L.C.","year":"2016","unstructured":"Coates L.C.; Kavanaugh A.; Mease P.J.; Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 2016,68(5),1060-1071","journal-title":"Arthritis Rheumatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"Kavanaugh A.","year":"2014","unstructured":"Kavanaugh A.; Mease P.J.; Gomez-Reino J.J.; Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014,73(6),1020-1026","journal-title":"Ann Rheum Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"i138","DOI":"10.1093\/rheumatology\/keu115.006","volume":"53","author":"Edwards Christopher J.","year":"2014","unstructured":"Edwards Christopher J.; Long-term 52-week results of palace 3, a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement. Rheumatology 2014,53(Suppl. 1),i138-i139","journal-title":"Rheumatology"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3899\/jrheum.151376","volume":"43","author":"Cutolo M.","year":"2016","unstructured":"Cutolo M.; Myerson G.E.; Fleischmann R.M.; A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol 2016,43(9),1724-1734","journal-title":"J Rheumatol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"Papp K.","year":"2015","unstructured":"Papp K.; Reich K.; Leonardi C.L.; Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015,73(1),37-49","journal-title":"J Am Acad Dermatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"Paul C.","year":"2015","unstructured":"Paul C.; Cather J.; Gooderham M.; Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015,173(6),1387-1399","journal-title":"Br J Dermatol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3899\/jrheum.110845","volume":"39","author":"Tillett W.","year":"2012","unstructured":"Tillett W.; Costa L.; Jadon D.; The ClASsification for Psoriatic ARthritis (CASPAR) criteria--a retrospective feasibility, sensitivity, and specificity study. J Rheumatol 2012,39(1),154-156","journal-title":"J Rheumatol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/1203475416631328","volume":"20","author":"AbuHilal M.","year":"2016","unstructured":"AbuHilal M.; Walsh S.; Shear N.; Mohn\u2019D., Scott Walsh, and Neil Shear. \u201cUse of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study. J Cutan Med Surg 2016,20(4),313-316","journal-title":"J Cutan Med Surg"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"Schafer P.","year":"2012","unstructured":"Schafer P.; Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 2012,83(12),1583-1590","journal-title":"Biochem Pharmacol"},{"key":"ref=16","first-page":"495","volume":"40","author":"Zerilli Tina","year":"2015","unstructured":"Zerilli Tina; Ocheretyaner Eric; Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. Pharmacy and Therapeutics 2015,40,495","journal-title":"Pharmacy and Therapeutics"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1177\/1203475416631328","volume":"20","author":"AbuHilal M.","year":"2016","unstructured":"AbuHilal M.; Walsh S.; Shear N.; Mohn\u2019D, Scott Walsh, and Neil Shear. \u201cUse of apremilast in combination with other therapies for treatment of chronic plaque psoriasis: a retrospective study. J Cutan Med Surg 2016,20(4),313-316","journal-title":"J Cutan Med Surg"},{"key":"ref=18","first-page":"21","author":"Danesh Melissa J.","year":"2015","unstructured":"Danesh Melissa J.; Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis. Dermatology online journal 2015,21","journal-title":"Dermatology online journal"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","volume":"74","author":"Mease P.J.","year":"2014","unstructured":"Mease P.J.; Armstrong A.W.; Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 2014,74(4),423-441","journal-title":"Drugs"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1479-5876-12-77","volume":"12","author":"Germano Valentina","year":"2014","unstructured":"Germano Valentina; Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-\u03b1 antagonists. J Transl Med 2014,12,77","journal-title":"J Transl Med"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/167914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T19:51:58Z","timestamp":1567972318000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/167914\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,31]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7,31]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573397115666181130094455","relation":{},"ISSN":["1573-3971"],"issn-type":[{"value":"1573-3971","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,31]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}